top of page

Novel Foods-authorized UK leader in CBD/THC transdermal patches & 3d-printed pills

Unique, differentiated, revenue driven medical cannabis company specializing in drug-in-adhesive CBD patches and 3D printed pills, offering a significant technology transfer opportunity

Listing ID:

16503339167

Licence(s) Held:

Novel Food Authorisation for Capsules & Oils

16503339167

Seeking outright divestiture of the brand, going-concern business, transferable technology, optional leased facility, and fixed assets for £1 million

Listing Details:

  • Branded leading supplier of specialized, niche drug-in-adhesive CBD (and future THC) patches in the UK

  • Aims to manufacture and build a range of transdermal patches for the over-the-counter CBD and medical cannabis markets

  • Currently has a fully built, 14,500 ft.² EU-GMP compliant manufacturing facility, fitted as a bespoke laboratory with various sized “clean room” labs

  • Undertaking labelling, packaging, retail sales, storage and distribution of excellent product mix of CBD Patches, CBD oils, CBD Capsules, CBD Vapes & CBD Cosmetics with future plans to add HC products

  • Products are sold successfully through the company’s website and through 3rdparty platforms

  • Strong focus on SEO marketing, brand exposure, customer engagement and subscribers, which has seen customer base grown by >250%

  • Exclusive worldwide agreement in place with a specialized technology company for the manufacture of unique cannabinoid patches for the medical and over-the-counter markets

  • Exclusive partnership with 3D printer manufacturer for pills which are then sold to clinics, pharmaceutical wholesalers or sold as CBD products in the OTC market (and future THC market potential)

  • Experienced leadership team with deep operating experience, marketing, R&D and a proven track record

  • In the process of applying for Manufacturing Specials License, WDA, Controlled Drug Storage and Human Tissue license

  • Developing proprietary IP for cannabinoid patch formulations and production

  • Strategically aligned roadmap, poised for rapid growth through R&D of THC patches and 3D printed pills through key partnerships with API providers

  • Facility comes with £250,000 of fixed assets

  • Acquisition includes a successful, interactive, revenue generating magazine focused on fibromyalgia which provides pain management solutions for patients

  • Seeking outright divestiture of the brand, going-concern business, transferable technology, optional leased facility, and fixed assets

  • There is an option to purchase the real estate

16503339167

Inquiry Form

Thanks for submitting! We have received your message and will get back to you within 24 hours. Until then, you can send an email to info@hydeadvisory.com

Contact-us-deal
bottom of page